drug

DAR-100A

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by New York State Psychiatric Institute, Washington Heights Community Service
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
NCT01519557Early Phase 1Completed

KOLs & investigators

1
Jeffrey A Lieberman, M.D.KOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
New York State Psychiatric Institute, Washington Heights Community Service
company
trial
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
EARLY_PHASE1
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Jeffrey A Lieberman, M.D.
KOL score 5
person